

References

Abou-Jawde R, Choueiri T, Alemany C, Mekhail T (2003). An overview of targeted treatments in cancer, *Clin. Ther.* **25**: 2121-2137

Abu-Surrah A, Al Allaf TAK, Klinga M, Ahlgren M (2003). Chiral palladium(II) and platinum(II) complexes of diaminocyclohexane: X-ray structures of (1R,2R)-(-)-1,2-diaminocyclohexane dihydrochloride and its corresponding oxalato platinum(II) complex, *Polyhedron* **22**: 1529-1534

Adhami VM, Aziz MH, Reagan-Shaw SR, Nihal M, Mukhtar H, Ahmad N (2004). Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery, *Mol. Cancer Ther.* **3**: 933-940

Ahn WS, Han YJ, Bae SM, kim T-H, Rho MS, Lee JM, Namkoong SE, Park YS, Kim CK, Sin J-I (2002). Differential suppression of human cervical cancer cell growth by adenovirus delivery of p53 *in vitro*: Arrest phase of cell cycle is dependent on cell line, *Jpn. J. Cancer Res.* **93**: 1012-1019

Ahrland S (1983). Factors influencing the affinities between metal ions and donor atoms in ligands of biological interest, *Inorg. Chim. Acta.* **79**: 94-96

Akdi K, Vilaplana R, Kamah S, Navarro J, Salas J, Gonzalez-Vilchez F (2002). Study of the biological effects and DNA damage exerted by a new dipalladium-Hmtpo complex on human cancer cells, *J. Inorg. Biochem.* **90**: 51-60

Albert A (1979). Differences in distribution: the first principle of selectivity., in *Selective toxicity: the physico-chemical basis of therapy*, Chapman and Hall, London p 51-95

Ali MA, Mirza AH, Butcher RJ, Tarafder MTH, Keat TB, Ali AM (2002). Biological activity of palladium(II) and platinum(II) complexes of the acetone Schiff bases of S-methyl- and S-benzylidithiocarbamate and the X-ray crystal structure of the

[Pd(asme)₂] (asme = anionic form of the acetone Schiff base of S-methyldithiocarbamate) complex, *J. Inorg. Biochem.* **92**: 141-148

Allen RT, Hunter WJ, Agrawal DK (1997). Morphological and biochemical characterization and analysis of apoptosis, *J. Pharmacol. Toxicol. Meth.* **37**: 215-228

Alverdi V, Giovagnini L, Marzano C, Seraglia R, Bettio F, Sitran S, Graziani R, Fregona D (2004). Characterisation studies and cytotoxicity assays of Pt(II) and Pd(II) dithiocarbamate complexes by means of FT-IR, NMR spectroscopy and mass spectrometry, *J. Inorg. Biochem.* **98**: 1117-1128

Amin OH, Al-Hayaly LJ, Al-Jibori SA, Al-allaf TAK (2004). Heterobimetallic complexes of palladium(II) and platinum(II) bridged by the ligand 5-phenyl-1,3,4-oxadiazole-2-thione, *Polyhedron* **23**: 2013-2020

Anderson R, Smit MJ, Van Rensburg CEJ (1993). Lysophospholipid-mediated inhibition of Na⁺, K⁺-adenosine triphosphatase is a possible mechanism of immunosuppressive activity of cyclosporine A, *Mol. Pharmacol.* **44**: 605-619

Artemov D, Solaiyappan M, Bhujwalla ZM (2001). Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumours, *Cancer Res.* **61**: 3039-3044

Baird IR, Smith MB, James BR (1995). Nickel(II) and nickel(0) complexes containing 2-pyridylphosphines ligands, including water-soluble species, *Inorg. Chim. Acta.* **235**: 291-297

Balcarová Z, Kašpárková J, Žáková A, Nováková O, Sivo M, Natile G, Brabec V (1998). DNA interactions of a novel platinum drug, *cis*-[PtCl(NH₃)₂(N7-Acyclovir)]⁺, *Mol. Pharmacol.* **53**: 846-855

Banditelli G, Bandini AL, Bonati F, Minghetti G (1982). A series of pyrazole adducts and pyrazolato derivatives of platinum(II) containing various chelating phosphines as ligands: characterisation, ¹H and ³¹P{¹H} NMR spectra, *Inorg. Chim. Acta.* **60**: 93-98

Barnard P, Baker M, Berners-Price S, Day D (2004). Mitochondrial permeability transition induced by dinuclear gold(I)-carbene complexes: potential new antimitochondrial antitumour agents, *J.Inorg.Biochem.* **98**: 1642-1647

Barnard P, Baker M, Skelton B, White A, Berners-Price S (2003). Synthesis and biological activities of some new gold(I)-carbene complexes: potential antimitochondrial antitumour agents. *J.Inorg.Biochem.* **96**, 99

Bartek J, Lukas J, Bartkova J (1999). Perspective; Defects in cell cycle control and cancer, *J. Pathol.* **187**: 95-99

Bell CF (1977). Properties of ligands and chelate rings, in *Principles and applications of metal chelation*, ed. Atkins PW, Holker JSE, and Holliday AK, Oxford University Press, p 9-29

Bell J, Norman R, Sadler P (1987). Coordination chemistry in biological media: reactions of antitumor Pt(II) and Au(III) complexes with cell culture media, *J. Inorg. Biochem.* **31**: 241-246

Berlin KRS, Ammini CV, Rowe TC (1998). Dequalinium induces a selective depletion of mitochondrial DNA from HeLa human cervical carcinoma cells, *Expt. Cell Res.* **245**: 137-145

Berners-Price SJ, Bowen RJ, Galettis P, Healy PC, McKeage MJ (1999a). Structural and solution chemistry of gold(I) and silver(I) complexes of bidentate pyridyl phosphines: selective antitumour agents, *Coord. Chem. Revs.* **185-186**: 823-836

Berners-Price SJ, Bowen RJ, Hambley TW, Healy PC (1999b). NMR and structural studies of gold(I) chloride adducts with bidentate 2-, 3- and 4-pyridyl phosphines, *J. Chem. Soc., Dalton Trans.* 1337-1346

Berners-Price SJ, Bowen RJ, Harvey PJ, Healy PC, Koutsantonis GA (1998). Silver(I) nitrate adducts with bidentate 2-, 3- and 4-pyridyl phosphines. Solution ^{31}P and [^{31}P - ^{109}Ag] NMR studies of 1:2 complexes and crystal structure of dimeric $[\{\text{Ag}(\text{d}2\text{pyrpe})(\mu\text{-d}2\text{pyrpe})\}_2][\text{NO}_3]_2 \cdot 2\text{CH}_2\text{Cl}_2$, *J. Chem. Soc., Dalton Trans.* 1743-1750

Berners-Price SJ, Colquhoun LA, Healy PC, Byriel KA, Hanna JV (1992). Copper(I) and gold(I) complexes with *cis*-bis(diphenylphosphino)ethylene. Crystal structures and ^{31}P cross-polarization magic angle spinning nuclear magnetic resonance studies, *J. Chem.Soc., Dalton Trans.*, 3357-3363

Berners-Price SJ, Johnson RK, Giovenella AJ, Faucette LF, Mirabelli CK, Sadler PJ (1988). Anti-microbial and anti-cancer activity of tetrahedral, chelated, diphosphine silver(I) complex: comparison with copper and gold, *J. Inorg. Biochem.* **33**: 285-295

Berners-Price SJ, Norman R, Sadler PJ (1987a). The autoxidation and proton dissociation constants of tertiary diphosphines: relevance of biological activity, *J. Inorg. Biochem.* **31**: 197-209

Berners-Price SJ, Sadler PJ (1986). Gold(I) complexes with bidentate tertiary phosphine ligands: Formation of annular vs. tetrahedral chelated complexes, *Inorg. Chem.* **25**: 3822-3827

Berners-Price SJ, Girard GR, Hill DT, Sutton BM, Jarrett PS, Faucette LF, Johnson RK, Mirabelli CK, Sadler PJ (1990). Cytotoxicity and antitumour activity of some tetrahedral bis(diphosphino)gold(I) chelates, *J. Med. Chem.* **33**: 1386-1392

Berners-Price SJ, Jarret PS, Sadler PJ (1987b). ^{31}P NMR studies of $[\text{Au}_2(\mu\text{-dppe})]^{2+}$ antitumour complexes. Conversion into $[\text{Au}(\text{dppe})_2]^+$ induced by thiols and blood plasma, *Inorg. Chem* **26**: 3074-3077

Berners-Price SJ, Sadler PJ (1987a). Phosphines in medicine, *Chem. Br.* 541-544

Berners-Price S, Johnson R, Mirabelli C, Faucette L, McCabe F, Sadler P (1987c). Copper(I) complexes with bidentate tertiary phosphine ligands: solution chemistry and anti-tumour activity, *Inorg. Chem.* **26**: 3383-3387

Berners-Price S, Mirabelli C, Johnson R, Mattern M, McCabe F, Faucette L, Sung C, Mong S, Sadler P, Croke S (1986). *In vivo* antitumor activity and *in vitro* cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride, *Cancer Res.* **46**: 5486-5493

Berners-Price S, Sadler P (1987b). Interaction of the antitumor Au(I) complex $[\text{Au}(\text{Ph}_2\text{P}(\text{CH}_2)_2\text{PPh}_2)_2]\text{Cl}$ with human blood plasma, red cells, and lipoproteins: ^{31}P and ^1H NMR studies, *J. Inorg. Biochem.* **31**: 267-281

Berners-Price S, Sadler P (1996). Coordination chemistry of metallodrugs: insights into biological speciation from NMR spectroscopy, *Coord. Chem. Revs* **151**: 1-40

Berthod A, Carda-Broch S (2004). Determination of liquid-liquid partition coefficients by separation methods, *J. Chromatogr.A* **1037**: 3-14

Bianchini C, Meli A, Oberhauser W (2003). Taking too many precautions in making a catalyst is never a loss of time: A lesson we learned at our own expense, *Organometallics* **22**: 4281-4285

Billington D, Jayson GG, Maltby PJ (1992). *Radioisotopes: Introduction to biotechniques*, BIOS Scientific Publishers Limited

Bowen RJ (1999). Hydrophilic bidentate phosphines and their group 11 complexes: potential antitumour agents, *Ph.D Thesis*

Bowen R, Garner A, Berners-Price S, Jenkins I, Sue R (1998). Convenient synthetic routes to bidentate and monodentate 2-, 3- and 4-pyridyl phosphines: potentially useful ligands for water-soluble complex catalysts, *J. Organomet. Chem.* **554**: 181-184

Broxterman HJ, Lankelma J, Hoekman K (2003). Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences, *Drug Resist. Updates* **6**: 111-127

Bruker. SAINT+. [6.02] (1999a). Madison, Winsconsin, USA, Bruker AXS Inc. *Computer Program*

Bruker. SHELXTL. [5.1] (1999b). Madison, Winsconsin, USA, Bruker AXS Inc. *Computer Program*

Budzelaar PHM, Frijns JHG, Orpen AG (1990). Synthesis and coordination chemistry of a new class of binucleating ligands: pyridyl-substituted diphosphines, *Organometallics* **9**: 1222-1227

Butler I, Licence P, Coles S, Hursthouse M (2000). The synthesis and characterisation of bis(phenylpyridylphosphino)ethane, *J. Organomet. Chem.* **598**: 103-107

Canovese L, Visentin F, Uguagliati P, Bianca FD, Fontana A, Crociani B (1996). Organometallic nucleophiles. A mechanistic study of halide displacement at saturated carbon by 2- and 4-pyridyl complexes of palladium(II) and platinum(II), *J. Organomet. Chem.* **525**: 43-48

Chen L (1988). Mitochondrial membrane potentials in living cells, *Annu. Rev. Cell. Biol.* **4**: 155-181

Chow K, Levason W, McAuliffe C (1974). Bidentate group VB chelates, Part VII. Some palladium(II) complexes with diphosphine, phosphine-arsine, and diarsine ligands, including some thiocyanate derivatives, *Inorg. Chim. Acta.* **15**: 79-83

Collins K, Jacks T, Pavletich NP (1997). The cell cycle and cancer, *Proc. Natl. Acad. Sci. U.S.A* **94**: 2776-2778

Conková E, Laciaková A, Pástorová B, Seidel H, Kováč G (2005). The effect of zearalenone on some enzymatic parameters in rabbits, *Toxicol. Lett.* **121**: 145-149

Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C (1993). A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1), *Biochem. Biophys. Res. Comm.* **197**: 40-45

Cossarizza A, Salvioli S (1997). Analysis of mitochondrial membrane potential with the sensitive fluorescent probe JC-1. The Purdue Cytometry CD-ROM **4**. Purdue University Cytometry Laboratories, West Lafayette, IN 1997, ISBN 1-890473-03-.

Crabtree RH (2005). NHC ligands versus cyclopentadienyls and phosphines as spectator ligands in organometallic catalysis, *J. Organomet. Chem.* **690**: 5451-5457

Daghriri H, Huq F, Beale P (2004). Studies on activities, cell up take and DNA binding of four multinuclear complexes of the form: [trans-PtCl(NH₃)₂ 2μ-trans-Pd(NH₃)₂-(H₂N(CH₂)_nNH₂)₂]Cl₄ (n = 4-7, *J. Inorg. Biochem* **98**: 1722-1733

Darzynkiewicz Z, Kapuscinski J, Carter S, Schmid F, Melamed M (1986). Cytostatic and cytotoxicity properties of pyronin Y: relation to mitochondrial localization of the dye and its interaction with RNA, *Cancer Res.* **46**: 5760-5766

Davies WC, Mann FG (1944). The stereochemistry of organic derivatives of phosphorus. Part I. The synthesis of acidic and basic dissymmetric tertiary phosphines. The optical resolution of phenyl-*p*-(carboxymethoxy)phenyl-*n*-butylphosphine sulphide, *J. Chem. Soc.* 276-283

Davis S, Weiss M, Wong J, Lampidis T, Chen L (1985). Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells, *J. Biol. Chem.* **260**: 13844-13850

Derby E, Reddy V, Kopp W, Nelson E, Baseler M, Sayers T, Malyguine A (2001). Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity, *Immunol. Lett.* **78**: 35-39

Desoize B, Madoulet C (2002). Particular aspects of platinum compounds used at present in cancer treatment, *Crit. Rev. Oncol. Hematol.* **42**: 317-325

Devic T, Batail P, Fourmigué M, Avarvari N (2004). Unexpected reactivity of PdCl₂ and PtCl₂ complexes of the unsaturated diphosphine *o*-Me₂TTF(PPh₂)₂ toward chloride abstraction with thallium triflate, *Inorg. Chem* **43**: 3136-3141

Dias N, Bailly C (2005). Drugs targeting mitochondrial functions to control tumour cell growth, *Biochem. Pharmacol.* **70**: 1-12

Dobashi Y (2005). Cell cycle regulation and its aberrations in human lung carcinoma, *Path. Inter.* **55**: 95-105

Don AS, Hogg PJ (2004). Mitochondria as cancer drug targets, *TRENDS in Molecular Medicine* **10**: 372-378

Durran SE, Smith MB, Dale SH, Coles SJ, Hursthouse MB, Light ME (2006). New pyridyl modified phosphines: Synthesis and late transition-metal coordination studies, *Inorg. Chim. Acta.* **359**: 2980-2988

Ecobichon DJ (1997). Acute toxicity studies, CRC press, New York p 43

Effendy, Hanna JV, Marchetti F, Martini D, Pettinari C, Pettinari R, Skelton BW, White AH (2004). Synthesis and spectroscopic characterisation (IR, ^1H and ^{31}P NMR, electrospray ionisation mass) of mono-, di-, tetra- and poly-meric complexes of silver(I) with diphosphine ligands: X-ray crystal structures of $\text{AgNO}_2:(\text{Ph}_2\text{PCH}_2\text{PPh}_2)$ (1:1)₂, $\text{AgNO}_2:(\text{Ph}_2\text{P}(\text{CH}_2)_3\text{PPh}_2)$ (1:1)₂, $\text{AgNO}_2:(\text{Ph}_2\text{PCH}=\text{CHPPh}_2)$ (2:1)₂ and $\text{AgNO}_2:\{p\text{-tolyl}\}_2\text{P}(\text{C}_{10}\text{H}_6)_2\text{P}(p\text{-tolyl})_2\}$ (1:1). *Inorg. Chim. Acta.* **357**, 1523-1537.

Elovaara E, Stockmann-Juvala H, Mikkola J, Gelboin HV (2007). Interactive effects of methyl tertiary-butyl ether (MTBE) and tertiary-amyl methyl ether (TAME), ethanol and some drugs: Triglyceridemia, liver toxicity and induction of CYP (2E1, 2B1) and phase II enzymes in female Wistar rats, *Environ. Toxicol. Pharmacol.* **23**: 64-72

Engelhardt LM, Patrick JM, Raston CL, Twiss P, White AH (1984). Crystal structures of bis[(ethane-1,2-diyl)-bis(diphenylphosphine)]-palladium(II) and -platinum(II) dichloride dichloromethane and dichloro[(ethane-1,2-diyl)bis(diphenylphosphine)]platinum(II) dichloromethane., *Aust. J. Chem.* **37**: 2193-2200

Espinet P, Soulantica K (1999). Phosphine-pyridyl and related ligands in synthesis and catalysis, *Coord. Chem. Revs.* **193-195**: 499-556

Espinosa E, Zamora P, Feliu J, Baron GM (2003). Classification of anticancer drugs--a new system based on therapeutic targets, *Cancer Treat. Rev.* **29**: 515-523

Ferguson G, Lough AJ, McAlees AJ, McCrindle R (1993). Bis[1,2-bis(diphenylphosphino)ethane]platinum(II) iodide bis(deuteriochloroform)solvate, *Acta. Cryst.* **C49**: 573-576

Fredericks EJ, Gindling MJ, Kroll LC, Storhoff BN (1994). Phosphine-nitrile ligands: the molecular structure of *cis*-2-diphenylphosphino-1-cyanocyclopentane and studies of the donor/acceptor properties of this and related ligands, *J. Organomet. Chem.* **465**: 289-296

Freshney RI (2005). Primary culture, in *Culture of animals: a manual of basic technique*, Wiley, New York p 175-197

Fruhauf NR, Oldhafer KJ, Holtje M, Kaiser GM, Fruhauf JH, Stavrou GA, Bader A, Broelsch CE (2004). A bioartificial liver support system using primary hepatocytes: a preclinical study in a new porcine hepatectomy model, *Surgery* **136**: 47-56

Galanski M, Yasemi A, Jakupec M, Keyserlingk N, Keppler B (2005). Synthesis, cytotoxicity, and structure-activity relationships of new oxaliplatin derivatives, *Monatshefte für Chemie* **136**: 693-700

Gambaro JJ, Hohman WH, Meek DW (1989). Synthesis and characterisation of trigonal-bipyramidal rhodium(I) complexes of tris(2-(diphenylphosphino)ethyl)phosphine and determination of a spectroscopic trans-influence series by $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy, *Inorg. Chem.* **28**: 4154-4159

Garrou PE. Δ_R ring contributions to ^{31}P NMR parameters of transition-metal-phosphorus chelate complexes. *Chem.Rev.* **81**, 229-266. 1981.

Giovannini C, Matarrese P, Scazzocchio B, Sanchez M, Masella R, Malorni W (2002). Mitochondria hyperpolarization is an early event in oxidized low-density lipoprotein-induced apoptosis in Caco-2 intestinal cells, *FEBS Letters* **523**: 200-206

- Golias CH, Charalabopoulos A, Charalabopoulos K (2004). Cell proliferation and cell cycle control: a mini review, *Int. J. Clin. Pract.* **58**: 1134-1141
- Gravance CG, Garner DL, Baumber J, Ball BA (1999). Assessment of equine sperm mitochondrial function using JC-1. *Theriogenology*, 1691-1703.
- Gravance CG, Garner DL, Miller MG, Berger T (2001). Fluorescent probes and flow cytometry to assess rat sperm integrity and mitochondrial function, *Reprod. Toxicol.* **15**: 5-10
- Grella G, Cabras M, Murineddu G, Pau A, Pinna G (2003). Synthesis and cytotoxicity of substituted 2-benzyl-naphth[2,3-d]imidazoles, *Eur. J. Pharm. Sci.* **20**: 267-272
- Gupta N, Price PM, Aboagye EO (2002). PET for *in vivo* pharmacokinetic and pharmacodynamic measurements, *Eur. J. Cancer* **38**: 2094-2107
- Hambley T (1997). The influence of structure on the activity and toxicity of Pt anti-cancer drugs, *Coord. Chem. Revs.* **166**: 181-223
- Hartmann T, Schmitt J (2004). Lipophilicity- beyond octanol/water: a short comparison of modern technologies, *Drug. Discov. Today* **1**: 431-439
- Hernandez MA, Rathinavelu A (2006). Chemical approaches to the treatment of cancer in *basic pharmacology: Understanding drug actions and reactions*. CRC Press, p 77-90
- Hoke GD, Macia RA, Meunier PC, Bugelski PJ, Mirabelli CK, Rush GF, Matthews WD (1989). In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit, *Toxicol. Appl. Pharmacol.* **100**: 293-306
- Hope EG, Levason W, Powell NA (1986). Coordination chemistry of higher oxidation states. Platinum -195 NMR studies of platinum(II) and platinum (IV) complexes of the bi- and multi-dentate phosphorus, arsenic and sulphur ligands, *Inorg. Chim. Acta.* **115**: 187-192
- Horbinski C, Chu CT (2005). Kinase signalling cascades in the mitochondrion: a matter of life or death, *Free Radic. Biol. Med.* **38**: 2-11

Huq F, Daghriri H, Yu JQ, Tayyem H, Beale P, Zhang M (2004). Synthesis, characterisation, activities, cell uptake and DNA binding of [trans-PtCl(NH₃)₂ [μ]-(H₂N(CH₂)₆NH₂) trans-PdCl(NH₃)₂](NO₃)Cl, *Eur. J. Med. Chem.* **39**: 947-958

Huth US, Schubert R, Peschka-Suss R (2006). Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging, *J. Controlled Release* **110**: 490-504

Jakupec MA, Galanski M, Keppler BK (2003). Tumour-inhibiting platinum complexes-state of the art and future perspectives, *Revs. Physiol. Biochem. Pharmacol.* **146**: 1-54

Jeffrey JC, Rauchfuss TB (1979). Metal complexes of hemilabile ligands. Reactivity and structure of dichlorobis(*o*-(diphenylphosphino)anisole)ruthenium(II), *Inorg. Chem.* **18**: 2658-2666

Jiang X, Wang X (2004). Cytochrome c-mediated apoptosis, *Annu. Rev. Biochem.* **73**: 87-106

Johnson L, Walsh M, Chen L (1980). Localization of mitochondria in living cells with rhodamine 123, *Proc. Natl. Acad. Sci. U.S.A* **77**: 990-994

Jones ND, Meessen P, Losehand U, Patrick BO, James BR (2005). Platinum(II) and Palladium(II) Complexes of Bisphosphine Ligands Bearing *o*-*N,N* DimethylanilinyI substituents; a Hint of Catalytic Olefin Hydration, *Inorg. Chem.* **44**: 3290-3298

Jones N, MacFarlane K, Smith M, Schutte R, Rettig SJ, James B (1999). Coordination Chemistry of the 2-Pyridyldiphosphine Ligands, (py)₂P(CH(CH₂)₃CH)P(py)₂ and (py)₂P(CH₂)₂P(py)₂ (py) 2-Pyridyl), with Platinum(II) and Ruthenium(II). Ruthenium-Catalyzed Hydrogenation of Imines, *Inorg. Chem.* **38**: 3956-3966

Khokhar AR, Xu Q, Siddik ZH (1990). Synthesis, characterization, and antitumor activity of 1,2-bis(diphenylphosphino) ethane platinum(II) and palladium(II) complexes, *J. Inorg. Biochem.* **39**: 117-123

- Kim JY, Lee YA, Park KM, Chae HK, Jung OS (2002). Molecular strands and related properties of silver(I) triflate with 3,3' - oxybispyridine vs 3,3' - thiobispyridine, *Bull. Korean Chem. Soc.* **23**: 1106-1110
- Koukourakis MI, Danielidis V (2005). Preventing radiation induced xerostomia, *Cancer Treat. Rev.* **31**: 546-554
- Koya K, Li Y, Wang H, Ukai T, Tatsuta N, Kawakami M, Chen LB (1996). MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation, *Cancer Res.* **56**: 538-543
- Kuduk-Jaworska J, Puszko A, Kubiak M, Pelczynska M (2004). Synthesis, structural, physico-chemical and biological properties of new palladium(II) complexes with 2,6-dimethyl-4-nitropyridine, *J. Inorg. Biochem.* **98**: 1447-1456
- Kurita-Ochiai T, Hashizume T, Yonezawa H, Ochiai K, Yamamoto M (2006). Characterisation of the effects of butyric acid on cell proliferation, cell cycle distribution and apoptosis, *FEMS Immunol. Med. Microbiol.* **47**: 67-74
- Kweekel DM, Gelderblom H, Guchelaar H-J (2005). Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy, *Cancer Treat. Rev.* **31**: 90-105
- Landis-Piowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, Yan B, Dou QP (2006). The proteasome as a potential target for novel anticancer drugs and chemosensitizers, *Drug Resist. Updates* **9**: 263-273
- Lassahn P-G, Lozan V, Wu B, Weller AS, Janiak C (2003). Dihalogeno(diphosphane)metal(II) complexes (metal = Co, Ni, Pd) as pre-catalysts for the vinyl/addition polymerisation of norbornene-elucidation of the activation process with $B(C_6F_5)_3/AlEt_3$ of $Ag[closo-1-CB_{11}H_{12}]$ and evidence for the in situ formation of "naked" Pd^{2+} as a highly active species, *Dalton Trans.* 4437-4450
- Liles D. Structure of 3e (2006). *Personal Communication*

Lipinski CA (2000). Drug-like properties and the causes of poor solubility and poor permeability, *J. Pharmacol. Toxicol. Meth.* **44**: 235-249

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, *Adv. Drug Deliv. Rev.* **23**: 3-25

Liu M-J, Yue PY-K, Wang Z, Wong RN-S (2005). Methyl protodioscin induces G₂/M arrest and apoptosis in K562 cells with the hyperpolarisation of mitochondria, *Cancer Lett.* **224**: 229-241

Liu X, Song D, Zhang Q, Tian Y, Liu Z, Zhang H (2006). Characterisation of drug-binding levels to serum albumin using a wavelength modulation surface plasmon resonance sensor, *Sens. Actuators B* **117**: 188-195

Lobana TS, Verma R, Hundal G, Castineiras A (2000). Metal-heterocyclic thione interactions. Heterocyclic 2-thiolates of platinum(II) and palladium(II): the crystal structures of first examples of *cis*- [M(η^1 -S-pyridine-2-thiolato)₂ (L-L)] {M = Pt, Pd, L-L = 1,2-bis(diphenylphosphino)ethane; M = Pt, L-L = 1,2-bis(diphenylphosphino)ethene } complexes, *Polyhedron* **19**: 899-906

Ludovico P, Rodrigues F, Almeida A, Silva MT, Barrientos A, Corte-Real M (2002), Cytochrome c release and mitochondrial involvement in programmed cell death induced by acetic acid in *saccharomyces cerevisiae*, *Mol. Biol. Cell* **13**: 2598-2606

Lundberg AS, Weinberg RA (1999). Control of the cell cycle and apoptosis, *Eur. J. Cancer* **35**: 1886-1894

Magner WJ, Tomasi TB (2005). Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes, *Mol. Immunol.* **42**: 1033-1042

Makin G, Dive C (2001). Apoptosis and cancer chemotherapy, *TRENDS Cell Biol.* **11**: S22-S26

- Mann CL, Cidlowski JA (2001). Glucocorticoids regulate plasma membrane potential during rat thymocyte apoptosis in vivo and in vitro, *Endocrinology* **142**: 421-429
- Marson A, van Oort AB, Mul WP (2002). In situ preparation of palladium diphosphane catalysts, *Eur. J. Inorg. Chem.* 3028-3031
- Mashima T, Tsuruo T (2005). Defects of the apoptotic pathway as therapeutic target against cancer, *Drug Resist. Updates* **8**: 339-343
- McIntyre P (2007). Rising tide of cancer poses global challenge. Cancer World: www.uicc.org
- McKeage M, Berners-Price S, Galettis P, Bowen R, Brouwer W, Ding L, Zhuang L, Baguley BC (2000). Role of lipophilicity in determining cellular uptake and anti-tumour activity of gold phosphine complexes, *Cancer Chemother. Pharmacol.* **46**: 343-350
- McKeage M, Maharaj L, Berners-Price S (2002). Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria, *Coord. Chem. Revs.* **232**: 127-135
- Meyer R, Brink S, van Rensburg CEJ, Joone GK, Gorls H, Lotz S (2005). Synthesis, characterization and antitumor properties of titanocene derivatives with thiophene containing ligands, *J. Organomet. Chem.* **690**: 117-125
- Miedaner A, DuBois DL, Curtis CJ (1993). Generation of Metal Formyl Complexes Using Nickel and Platinum Hydrides as Reducing Agents. *Organometallics* **12**, 299-303.
- Minahan DMA, Hill WE, McAuliffe CA (1984). An investigation of the chelate effect: the binding of bidentate phosphine and arsine chelates in square-planar transition metal complexes, *Coord. Chem. Revs.* **55**: 31-54
- Mingos DMP (1998). Transition elements (d block), lanthanides, and actinides (f block elements), in *Essential Trends in Inorganic Chemistry*, Oxford University Press, Inc., New York, p 273-388

- Modica-Napolitano JS, Singh KV (2002). Mitochondria as targets for detection and treatment of cancer, *Expert Revs. Mol. Med.* 1-19
- Mohlala MS, Guzei IA, Darkwa J, Mapolie SF (2005). Pyridine linker pyrazolyl palladium complexes: Synthesis, characterization and ethylene polymerization activity, *J. Mol. Catal. A: Chem.* **241**: 93-100
- Mollinedo F, Gajate C (2006). Fas/CD95 death receptor and lipid rafts: New targets for apoptosis-directed cancer therapy, *Drug Resist. Updates* **9**: 51-73
- Molnár L, Keserü GM, Papp A, Gulyás Z, Darvas F (2004), A neural network based prediction of octanol-water partition coefficients using atomic5 fragmental descriptors., *Bioorg. Med. Chem. Lett.* **14**: 851-853
- Morris KT, Song TJ, Fong Y (2006). Recent advancements in diagnosis and treatment of metastatic colorectal cancer to the liver, *Surg. Oncol.* **15**: 129-134
- Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, *J. Immunol. Methods* **65**: 55-63
- Moura EM, Dickman MH, Siebald HGL, Gama GJ (1999). Synthesis, characterisation and structure determination of $\{[\text{CpRu}(\text{Cl})]_2 (\eta^2, \mu_2\text{-dppe})_2\}$ complexes ($X = \text{Cl}, \text{N}_3$; $\text{dppe} = \text{Ph}_2\text{PCH}_2\text{CH}_2\text{PPh}_2$), *Polyhedron* **18**: 2899-2906
- Nadakavukaren KK, Nadakavukaren JJ, Chen LB (1985), Increased rhodamine 123 uptake by carcinoma cells, *Cancer Res.* **45**: 6093-6099
- Newkome GR (1993). Pyridylphosphines, *Chem.Rev.* **93**: 2067-2089
- Nigg EA (1995). Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle, *Bioassays* **17**: 471-480
- Nolte F, Friedrich O, Rojewski M, Fink RHA, Schrezenmeier H, Körper S (2004). Depolarisation of the plasma membrane in the arsenic trioxide (As_2O_3)- and anti-CD95-induced apoptosis in myeloid cells, *FEBS Letters* **578**: 85-89
- Nygren P, Larsson R (2003). Overview of the clinical efficacy of investigational anticancer drugs, *J. Intern. Med.* **253**: 46-75

Oberhauser W, Bachmann C, Bruggeller P (1995). Palladium (II) and platinum (II) complexes of cis-1,2-bis(diphenylphosphino)ethene: completely planar structures due to p bonding in the case of platinum (II), *Inorg. Chim. Acta.* **238**: 35-43

Oberhauser W, Bachmann C, Stampfl T, Bruggeller P (1997a). Binuclear palladium(II), platinum(II) and platinum(IV) complexes containing 1,2-bis(diphenylphosphino)acetylene: different orientations of the diphosphine-bridges due to metal-phosphorus d[pi]-d[pi] back bonding, *Inorg. Chim. Acta.* **256**: 223-234

Oberhauser W, Bachmann C, Stampfl T, Haid R, Bruggeller P (1997b). Structural differences in nickel(II) and palladium(II) complexes containing cis-1,2-bis(diphenylphosphino)ethene or 1,2-bis(diphenylphosphino)ethane, *Polyhedron* **16**: 2827-2835

Oberhauser W, Bachmann C, Stampfl T, Haid R, Langes C, Rieder A, Bruggeller P (1998). Nickel(II), palladium(II), platinum(II) and platinum(IV) complexes of cis-1,2-bis(diphenylphosphino) ethene and nitrogen-containing heterocycles or sulfur ligands, *Inorg. Chim. Acta.* **274**: 143-154

Ormerod MG (2002). Investigating the relationship between the cell cycle and apoptosis using flow cytometry, *J. Immunol. Meth.* **265**: 73-80

Orrenius S (2004). Mitochondrial regulation of apoptotic cell death, *Toxicol. Lett.* **149**: 19-23

Owa T, Yoshino H, Yoshimatsu K, Nagasu T (2001), Cell cycle regulation in G1 phase: A promising target for the development of new chemotherapeutic anticancer agents, *Curr. Med. Chem.* **8**: 1487-1503

Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat K, Sonsuz A (2006). Severe liver enzyme elevations after three years of Olanzapine treatment: A case report and review of Olanzapine associated hepatotoxicity, *Prog. Neuro-psychopharm. Biol. Psych.* **30**: 1163-1166

Park WH, Seol JG, Kim ES, Kang WK, Im YH, Jung CW, Kim BK, Lee YY (2002). Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis, *Brit. J. Haematol.* **119**: 400-407

- Poole SK, Poole CF (2003). Separation methods for estimating octanol-water partition coefficients., *J. Chromatogr. B* **797**: 3-19
- Popiolkiewicz, Polkowski K, Skierski JS, Mazurek AP (2005). In vitro toxicity evaluation in the development of new anticancer drugs-genistein glycosides, *Cancer Lett.* **229**: 67-75
- Radosevic K, Tom C, van Graft M, de Grooth BG, Greve J (1993). A flow cytometric study of the membrane potential of natural killer and K562 cells during the cytotoxic process, *J. Immunol. Meth.* **161**: 119-128
- Ray RS, Rana B, Swami B, Venu V, Chatterjee M (2006). Vanadium mediated apoptosis and cell cycle arrest in MCF-7 cell line, *Chem. Biol. Interact.* **163**: 239-247
- Reed JC, Jurgensmeier JM, Matsuyama S (1998). Bcl-2 family proteins and mitochondria, *Biochim. Biophys. Acta.* **1366**: 127-137
- Reedijk J (2003). New clues for platinum antitumour chemistry: Kinetically controlled metal binding to DNA, *Proc. Natl. Acad. Sci. USA* **100**: 3611-3616
- Rideout DC, Bustamante A, Patel J (1994). Mechanism of inhibition of FaDu hypopharyngeal carcinoma cell growth by tetraphenylphosphonium chloride, *Int. J. Cancer* **57**: 247-253
- Rideout D, Calogeropoulou T, Jaworski J, Dagnino R, McCarthy M (1989). Phosphonium salts exhibiting selective anti-carcinoma activity *in vitro*, *Anti-Cancer Drug Design* **4**: 265-280
- Ronconi L, Sadler PJ (2007). Using coordination chemistry to design new medicines, *Coord. Chem. Revs.* **251**: 1633-1648
- Roodt A, Otto S, Steyl G (2003). Structure and solution behaviour of rhodium(I) Vaska-type complexes for correlation of steric and electronic properties of tertiary phosphines ligands., *Coord. Chem. Revs.* **245**: 121-137

Roques B, Pelaprat D, le Guen I, Porcher G, Gosse C, le Pecq J (1979). DNA bifunctional intercalators: Antileukemic activity of new pyridocarbazole dimers, *Biochem. Pharmacol.* **28**: 1811-1815

Rottenberg H, Wu S (1998). Quantitative assay by flow cytometry of the mitochondrial membrane potential in intact cells, *Biochim. Biophys. Acta.* **1404**: 393-404

Sadler P. Metal complexes in medicine: Design and mechanism of action. *J. Inorg. Biochem.* **67**[1-4], 4. 1997.

Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A (1997). JC-1, but not DiOC₆ (3) or rhodamine 123, is a reliable fluorescent probe to assess ψ changes in intact cells: implications for studies on mitochondria functionality during apoptosis, *FEBS Lett.* **411**: 77-82

Sanchez RI, Mesia-Vela S, Kauffman FC (2001). Challenges of cancer drug design: A drug metabolism perspective, *Curr. Cancer Drug Tar.* **1**: 1-32

Sané A-T, Cantin AM, Paquette B, Wagner JR (2004). Ascorbate modulation of H₂O₂ and camptothecin-induced cell death in Jurkat cells, *Cancer Chemoth. Pharm.* **54**: 315-321

Schafer KA (1998). The Cell Cycle: A Review, *Vet. Pathol.* **35**: 461-478

Schrauwen P, Hoeks J, Hesselink MKC (2006). Putative function and physiological relevance of the mitochondrial uncoupling protein-3: Involvement in fatty acid metabolism?, *Prog. Lipid. Res.* **45**: 17-41

Schurig J, Meinema H, Timmer K, Long B, Casazza A (1989). Antitumor activity of bis[bis(diphenylphosphino)alkane and alkene] group VII metal complexes, *Prog. Clin. Biochem. Med.* **10**: 205-216

Scott SL, Gumerlock PH, Beckett L, Li Y, Goldberg Z (2004). Survival and cell cycle kinetics of human prostate cancer cell lines after single- and multifraction exposures to ionisation radiation, *Int. J. Radiation Oncology Biol. Phys.* **59**: 219-227

Screnci D, McKeage M (1999). Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches, *J. Inorg. Biochem.* **77**: 105-110

Selikoff I (2005). Global action against cancer. www.uicc.org .

Sheldrick GM. SADABS. [2004/1]. 1996. Germany, University of Göttingen. Computer Program

Shiu M-H (2003). A surgeon's look at the treatment of cancer, *Ann.Coll.Surg.H.K* **7**: B7-B17

Skelton LA, Ormerod MG, Titley J, Kimbell R, Brunton LA, Jackman AL (1999). A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus, *Brit. J. Cancer* **79**: 1692-1701

Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, Steele GD, Chen LB (1991). Intracellular heterogeneity in mitochondrial membrane potentials revealed by a j-aggregate-forming lipophilic cation JC-1, *Proc. Natl. Acad. Sci. USA* **88**: 3671-3675

Smith P, Hoke G, Alberts D, Bugelski P, Lupo P, Mirabelli C, Rush G (1989). Mechanism of toxicity of an experimental bidentate phosphine gold complexed antineoplastic agent in isolated rat hepatocytes, *J. Pharmacol. Exp. Ther.* **249**: 944-950

Song Y, Vittal J, Srinivasan N, Chan S, Leung P (1999). Synthesis and anti-cancer activities of a pair of enantiomeric gold(I) complexes containing sulfanyl-substituted P-stereogenic phosphines, *Tetrahedron-Asymmetr.* **10**: 1433-1436

Spek AL (2003). Xray, *J.Appl.Cryst.* **36**: 7-13

Stockland RA, Levine AM, Giovine MT, Guzei IA, Cannistra JC (2004). Reductive elimination from metal phosphonate complexes: Circumvention of competing protonolysis reactions., *Organometallics* **23**: 647-656

Summerhayes I, Lampidis T, Bernal S, Nadakavukaren J, Nadakavukaren K, Shepherd E, Chen L (1982). Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells, *Proc. Natl. Acad. Sci. U.S.A* **79**: 5296

Sun X, Wong JR, Song K, Hu J, Garlid KD, Chen LB (1994). AA1, a newly synthesized monovalent lipophilic cation, expresses potent *in vivo* antitumor activity, *Cancer Res.* **54**: 1465-1471

Susin SA, Zamzami N, Kroemer G (1998). Mitochondria as regulators of apoptosis: doubt no more, *Biochim. Biophys. Acta.* **1366**: 151-165

Suyama K, Shapiro I, Guttman M, Hazan RB (2002). A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor, *Cancer Cell* **2**: 301-314

Tanase T, Kawahara K, Ukaji H, Kobayashi K, Yamazaki H, Yamamoto Y (1993). Electrochemical preparation and characterisation of binuclear palladium(I) complexes containing aromatic isocyanide and chelating diphosphine ligands, *Inorg. Chem.* **32**: 3682-3688

The National Cancer Registry (2003). Cancer statistics 1997.

Thirupathi N, Amoroso D, Bell A, Protasiewicz JD (2005). Synthesis and reactivity of cationic palladium phosphine carboxylate complexes, *Organometallics* **24**: 4099-4102

Thomas N, Goodyer ID (2003). Stealth sensors: real-time monitoring of the cell cycle, *TARGETS* **2**: 26-33

Tiekink E (2002). Gold derivatives for the treatment of cancer, *Crit. Rev. Oncol. Hemat.* **42**: 225-248

Tiekink E (2003). Gold derivatives for the treatment of cancer. 2003. World Gold Council.

Tolman CA (1977). Steric effects of phosphorus ligands in organometallic chemistry and homogenous catalysis, *Chem. Rev.* **77**: 313-348

Trécourt F, Breton G, Bonnet V, Mongin F, Marsais F, Quéguiner G (2000). New syntheses of substituted pyridines via bromine-magnesium exchange, *Tetrahedron* **56**: 1349-1360

Tsuruo T, Lida H, Tsukagoshi S, Sakurai Y (1982). Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors, *Cancer Res.* **42**: 4730-4733

Uhlig E, Maaser M (1966). Komplexchemisches Verhalten von funktionellen Derivaten des 2-äthyl-pyridins. VI. Das -(Bis-phenyl-phosphino)-äthyl-pyridin-(2), *Z. Anorg. Allg. Chem.* **344**: 205-213

Vámosi G, Bodnár A, Damjanovich S, Nagy P, Varga Z, Damjanovich L (2006). The role of supramolecular protein complexes and membrane potential in transmembrane signalling processes of lymphocytes, *Immunol. Lett.* **104**: 53-58

van Engeland M, Ramaekers F, Schutte B, Reutelingsperger C (1996). A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture, *Cytometry* **24**: 131-139

Vermes I, Haanen C, Reutelingsperger C (2000). Flow cytometry of apoptotic cell death, *J. Immunol. Meth.* **243**: 167-190

Vermes I, Haanen C, Steffens-Nakken H, Reutellingsperger C (1995). A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V, *J. Immunol. Meth.* **184**: 39-51

Vermeulen K, van Bockstaele DR, Berneman ZN (2003). The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer, *Cell Prolif.* **36**: 131-149

Vink SR, van Blitterswijk WJ, Schellens JHM, Verheij M (2007). Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy, *Cancer Treat. Rev.* **33**: 191-202

- Vogler A, Kunkely H (2002). Excited state properties of transition metal phosphine complexes., *Coord. Chem. Revs.* **230**: 243-251
- Wang RB, Kuo CL, Lien LL, Lien EJ (2003). Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors, *J. Clin. Pharm. Ther.* **28**: 203-228
- Wang Z-B, Liu Y-Q, Cui Y-F (2005). Pathways to caspase activation, *Cell Biol. Int.* **29**: 489-496
- Weiss J, Wong J, Chul S, Bleday R, Salem R, Steele G, Chen LB (1987). Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation, *Proc. Natl. Acad. Sci. U.S.A* **84**: 5444-5448
- Westland A (1965). Five co-ordinate Palladium (II) and Platinum (II), *J. Chem. Soc.* 3060-3067
- Workman P (2001). New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges, *Curr. Cancer Drug Tar.* **1**: 33-47
- World Health Organisation (2003). Global cancer rates could increase by 50% to 15 million by 2020. www.who.int .
- World Health Organisation (2005). www.who.int.
- Xie Y, James BR (1991). Synthesis and chemistry of 2-pyridyl(phosphine) complexes of Pt(0), *J. Organomet. Chem.* **417**: 277-288
- Yu Q (2006). Restoring p53-mediated apoptosis in cancer cells: New opportunities for cancer therapy, *Drug Resist. Updates* **9**: 19-25
- Zeevaart JR, Jansen DR, Filomena BM, Abrunhosa A, Gomes C, Metello L, Kolar ZI, Krijger GC, Louw WKA, Dormehl IC (2004). Comparison of the predicted in vivo behaviour of the Sn(II)-APDDMP complex and the results as studied in a rodent model, *J. Inorg. Biochem.* **98**: 1521-1530

Zeevaart J, Jarvis N, Louw W, Jackson G (2001). Metal-ion speciation in blood plasma incorporating the tetrphosphonate, N,N-dimethylenephosphonate-1-hydroxy-4-aminopropilydenediphosphonate (APDDMP), in therapeutic radiopharmaceuticals, *J. Inorg. Biochem.* **83**: 57-65

Zhang ZZ, Cheng H (1996). Chemistry of 2-(diphenylphosphino)pyridine, *Coord. Chem. Revs.* **147**: 1-39

Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, Liu ET, Kohn KW, Pommier Y, Weinstein JN (2002). Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: Microarray analysis of dose- and time-dependent effects, *Cancer Res.* **62**: 1688-1695

Zhuravel CD, Glueck DS (1999). Synthesis and structure of dinuclear diphosphine-bridged palladium(II) complexes, *Organometallics* **18**: 4673-4676

Zimmermann S, Menzel CM, Stüben D, Taraschewski H, Sures B (2003). Lipid solubility of the platinum group metals Pt, Pd and Rh in dependence on the presence of complexing agents, *Environ. Pollut.* **124**: 1-5